Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:52 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
GM-CLAG in Relapsed/Refractory FLT3-mutated AML
NCT05330377 · Ayman H Qasrawi · PHASE1 · withdrawn · last registry update 2023-04-25 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor withdrew funding” | Open Targets' class: business administrative | Registry record, Ayman H Qasrawi |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FLT3 in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-02-29Phase 3 first posted: The Second Affiliated Hospital of Kunming Medical University, a drug against FLT3 (NCT06285136)
- 2024-02-28Results posted on the registry: M.D. Anderson Cancer Center, Azacitidine + Cytarabine (NCT01892371)
- 2024-02-08Results posted on the registry: Novartis Pharmaceuticals, Midostaurin + Cytarabine (NCT03379727)
- 2023-10-10Phase 3 first posted: The Second Affiliated Hospital of Kunming Medical University, a drug against FLT3 (NCT06073730)
- 2022-10-05Results posted on the registry: Daiichi Sankyo, Chemotherapy + Quizartinib (NCT02668653)
- 2022-06-27Results posted on the registry: Astellas Pharma Global Development, Inc., Gilteritinib + Placebo (NCT02927262)
- 2022-06-24Results posted on the registry: Astellas Pharma Global Development, Inc., gilteritinib + atezolizumab (NCT03730012)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision